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Using flow cytometry we analyzed absolute and relative proportions of 
hematopoietic stem and progenitors cells (HSPC) populations including hematopoietic stem 
cells (HSC), multipotent progenitors (MPP), multilymphoid progenitors (MLP) and pro B 
cells from bone marrow of patients with  mature B cell malignancies and in healthy controls. 
We found lower absolute and relative numbers of MLP and higher relative numbers of HSC 
were observed in patients when compared to age-matched controls irrespective of bone 
marrow (BM) involvement. On the other hand significantly decreased absolute numbers of 
MPP were observed only in patients who had their BM infiltrated by disease. We also 
confirmed published data showing increasing absolute and relative percentages of MLP with 
increasing age, decreasing relative percentages of HSC with increasing age, and decreasing 
absolute and relative pro B cell frequencies with increasing age in healthy subjects. While 
decreased absolute and relative pro B cell numbers were also found in patient samples as 
age increased, no significant correlations were detected in patients HSC, MPP or MLP 
populations. Age-related sub-analysis of PTs samples demonstrated that most of the disease 
associated changes in HSPC frequencies were observable more prominently in the elderly 
(>45 years). Not surprisingly, the absolute numbers of all analyzed HSPC populations with 
the exception of HSC, i.e. MPP, MLP and pro B, negatively correlated with the extent of 
BM infiltration. Interestingly, the relative numbers of HSC and MLP demonstrated negative 
correlation with the BM infiltration, while relative numbers of MPP showed positive 
correlation with the extent of BM infiltration. Gene expression analysis of selected key 
regulators of hematopoiesis in patient HSCs was compared to healthy control HSCs. We 
showed altered transcription of selected key regulators of hematopoiesis, apoptosis and cell 
cycle progression. Our data point more complex deregulation of hematopoiesis than mere 
spacial oppression of hematopoiesis by presence of malignant B cells.  
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ABSTRACT (Czech) 
U pacientů s nádorem ze zralých B buněk a u zdravých kontrol byly analyzovány 
absolutní a relativní podíly populací hematopoetických kmenových buněk a progenitorů 
(HSPC), včetně hematopoetických kmenových buněk (HSC), multipotentních progenitorů 
(MPP), multilymphoidních progenitorů (MLP) a pro B buněk. Identifikovali jsme nižší 
absolutní a relativní zastoupení MLP a vyšší relativní zastoupení HSC u pacientů, bez 
ohledu na postižení kostní dřeně (BM), ve srovnání s kontrolami. U pacientů s infiltrací 
kostní dřeně maligními buňkami jsme navíc pozorovali významně snížené absolutní počty 
MPP. U zdravých subjektů jsme potvrdili dříve publikované výsledky ukazující zvýšení 
absolutního a relativního zastoupení MLP s věkem, klesající relativní zastoupení HSC s 
věkem a klesající absolutní a relativní koncentraci pro B buněk s věkem. Snížené absolutní a 
relativní koncentrace pro B buněk byly zjištěny také u studovaných pacientů (PT) v korelaci 
s věkem. Nižší absolutní a relativní koncentrace MLP a vyšší relativní koncentrace HSC 
byly pozorovány u pacientů ve srovnání s věkově odpovídajícími kontrolami bez ohledu na 
infiltraci kostní dřeně (KD). Absolutní koncentrace MPP byla významně snížená pouze u 
pacientů, kteří měli maligními buňkami infiltrovanou kostní dřeň. Porovnání změn 
v zastoupení HSPC ve vzorcích kostní dřeně pacientů v závislosti na věku ukázalo, že tyto 
změny jsou významné zejména u starších osob (> 45 let). Absolutní koncentrace MPP, MLP 
a pro B, s výjimkou HSC, negativně korelovaly s mírou infiltrace BM. Zajímavé je, že 
relativní koncentrace HSC a MLP vykazovaly negativní korelaci s infiltrací BM, zatímco 
relativní koncentrace MPP vykazoval pozitivní korelaci s mírou infiltrace BM. Analýza 
exprese vybraných klíčových regulátorů hematopoézy u HSC ukázala změněnou transkripci 
vybraných klíčových regulátorů hematopoézy, apoptózy a progrese buněčného cyklu u 
pacientů v porovnání se zdravými kontrolami a zvýšenou transkripční aktivitu v 
hematopoetických kmenových buňkách pacientů. Naše výsledky ukazují komplexní 
deregulaci krvetvorby přítomností maligních B lymfocytů.  
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1 INTRODUCTION  
1.1 Mature B-cell neoplasms 
Mature B-cell malignancies comprise a heterogeneous group of lymphoproliferative 
disorders (LPD) including chronic lymphocytic leukemia (CLL), diffuse large B-cell 
lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), multiple 
myeloma (MM) and other diseases (Figure 2). Within this broad group, non-Hodgkin’s 
lymphoma represents the most common hematological cancer in adults and approximately 
88% percent of this group in adults is comprised of B-cell non-Hodgkin’s lymphoma 
(,NHL) [1-3]. These neoplastic diseases present with various clinical pictures, some are slow 
growing yet incurable and some are very aggressive or rapidly develop and are fatal, yet are 
often curable [4, 5]. B-cell non-Hodgkin’s lymphoma are considered to arise along the 
different steps of B-cell development, particularly from germinal or post-germinal center B-
cells due to aberrant somatic hyper mutation or class switch recombination. NHLs arise by 
accumulating genetic aberrations that induce a selective growth advantage of the malignant 
clone in a multistep way (Figures 1, 2). Repeated and recurrent mutations which are thought 
to usually occur at the various B-cell differentiation stages lead to deregulated expression of 
oncogenes that usually control proliferation, cell survival and differentiation. It has however 
been noted that these mutations alone are not enough for lymphoma development and as 
such secondary genetic modifications are necessary to reach full malignant transformation 
[6]. The most entities common in this group of lymphomas includes DLBCL, FL, CLL/SLL, 
MCL, MM and Burkitt lymphoma among others (Figure 2).  
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Figure 1. Normal B-cell development showing the various B-cell precursors and B-cell subsets 
beginning at the level of the hematopoietic stem cell to level of the progenitor B-cells. Middle 
and last panels show secondary B-cell development in the secondary lymphoid organs including 
spleen and the lymph nodes. Normal B-cells are generated in the bone marrow, migrate to the 
periphery and following developmental checkpoint selection, become IgM+IgD+ mature naive B-
cells. When these cells are activated by cognate antigen in the presence of T-cell help, they undergo 
a germinal center (GC) reaction where they rapidly proliferate; this results in clonal expansion and 
subsequent somatic hypermutation. B-cells bearing antibodies with high affinity for cognate antigen 
which survive the GC reaction can undergo class-switch recombination to IgG, IgA or IgE isotypes 
and ultimately differentiate into memory B-cells, antibody-secreting plasmablasts or plasma cells. 
After subsequent encounter with the same cognate antigen, memory B-cells can proliferate or 
differentiate directly into antibody-secreting cells. Figure adapted from Pieper et al. 2013 [7]. 
 
The current understating is that the bone marrow stage of B-cell development i.e. 
from the level of the HSC to the immunoglobin expressing immature or mature but naive B-
cell (or pre B cell in some cases) is normal. This stage is antigen independent. The naïve B 
cells then exit the bone marrow and move to secondary lymphoid organs where they meet 
antigen for first time. 
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Figure 2. Key steps in B-cell development and various points of origin for mature B-cells 
neoplasms. The steps of normal B-cell differentiation and diversification of the antibody repertoire 
are indicated in continuous arrows. Steps that proceed abnormally, leading to the development of 
human B-cell leukemia and lymphoma, are indicated in dashed arrows. ALL, acute lymphoblastic 
leukemia; CLL, chronic lymphocytic leukemia; MCL, mantle cell lymphoma; GC-DLBCL, germinal 
center diffuse large B-cell lymphoma; FL, follicular lymphoma; ABC-DLBCL, activated B cell–like 
DLBCL; MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma. 




   6 
 
In the secondary lymphoid organs the genetic events that lead to lymphoma-genesis 
occur during the stages of somatic hyper mutations, clonal expansion, differentiating and 
isotype switching. These processes take place in the germinal center (giving rise to DLBCL, 
FL, CLL), the mantle zone (giving rise to MCL) and in the post germinal center where 
plasma cells arise among others (giving rise to MGUS and MM) (Figure 2) [9]. 
For decades it had been believed that the transformation events occurred exclusively 
at the stage of mature lymphocytes and as a consequence that the hematopoietic stem and 
progenitors cells (HSPC) retained their genetic integrity. Recently, several key reports 
questioned this hypothesis [10, 11]. It has been demonstrated that HSC might harbor 
mutations that favor B cell commitment, and predispose to expansion of monoclonal B-cell 
populations (e.g. monoclonal B-cell lymphocytosis) that are prone to “progression” to LPD, 
e.g. in CLL [10, 12]. In addition to such HSC intrinsic alterations, it was shown that 
hematopoiesis in patients with mature LPD might be quantitatively and qualitatively 
deregulated by the presence of malignant lymphocytes or plasma cells in the bone marrow 
microenvironment [13, 14]. 
Finally, Kuranda et al., 2011, as well as other researchers, brought evidence of age-related 
changes in the hematopoiesis of normal healthy individuals [15]. Residual “normal” 
hematopoiesis in patients with mature LPD thus might be influenced by at least three key 
factors: 1. HSC-intrinsic mutations (that might predispose to the development of LPD),  
2. Direct or indirect impact of malignant lymphocytes present in the bone marrow or extra 
medullary space, 3. Age-related changes.  
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 Diffuse large B-cell lymphoma 
DLBCL constitutes about 30% of all cases of B-NHL in Caucasians making it the 
most common adult non-Hodgkin’s lymphoma in the west. It is a heterogeneous group of 
transformed and large B-cells defined by WHO guidelines of 2008 as diffuse growth of 
neoplastic large lymphoid cells with a nuclear size equal to or bigger than normal 
macrophage nuclei [16]. This lymphoma is generally aggressive and is clinically, 
histologically, pathologically and genetically diverse [16, 17]. Etiologically DLBCL can 
arise de novo or can result from the transformation of low grade lymphomas especially 
small lymphocytic lymphoma (Richter transformation) and FL [17]. The DLBCL cells have 
undergone somatic mutation of immunoglobin genes and generally express the pan B-cell 
antigens (CD19, CD20, CD22, Pax5 and CD79a). Using gene expression profiling 3 
different molecular subtypes have been described: germinal center B cell-like DLBCL 
(GCB-DLBCL), activated B cell-like DLBCL (ABC-DLBCL) and primary mediastinal B-
cell lymphoma (PMBL) (Figure 3) [18]. The GCB-DLBCL is characterized by the 
expression of genes which occur in normal germinal centers (e.g. BCL6, CD10, and CD38); 
the ABC-DLBCL is characterized by genes which are found during in vitro activation of 
peripheral blood B-cells, while the third type did not express either set of genes. Due to the 
heterogeneity of the DLBCL group other variant schemes are used e.g. DLBCL not 
otherwise specified (DLBCL-NOC) which includes the common morphologic variants 
centroblastic, immunoblastic and anaplastic DLBCL variants and the molecular subgroups 
germinal center B cell-like and non-germinal center B cell-like. Other specified variants are 
T-cell/histiocyte rich large B-cell lymphoma, primary DLBCL of the CNS, primary 
Cutaneous DLBCL, leg type and EBV-positive DLBCL of the elderly. The median age at 
diagnosis is 65 years and generally the disease is potentially curable [19]. 
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Figure 3. Key oncogenic pathways in diffuse large B-cell Lymphoma. It is postulated that both 
types of DLBCL arise from normal stages of B-cell development with GCB-DLBCL arising from 
centroblasts and the ABC-DLBCL variant arising from a plasmatic type cell just before it exists the 
germinal center. Oncogenic events that define these two major subtypes are listed. Cb, centroblast; 
Cc, centrocyte; Pb, plasmablast; Pc, plasma cell; DHIT, double-hit lymphoma; del, deletion; BCR, 
B-cell receptor. Figure adapted from Laurie et al., 2015 [20]. 
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 Follicular lymphoma  
Follicular lymphoma (FL) is an indolent lymphoid neoplasm derived from germinal 
center B-cells. It results from malignant transformation of mature B-cells, and is 
characterized by the aberrant proliferation of germinal center (GC)-like B-cells in the 
lymphoid organs. The cells express germinal center markers such as CD10 and BCL6 and 
are organized in follicles. It is a slow growing disease with a high response to therapy 
though it is generally considered incurable with median survival rates of about 10 years. 
Though the disease is indolent, transformation to the more aggressive DLBCL can occur 
[21]. Histologically FL exhibits a nodular or follicular pattern. It is composed of two types 
of cells; centrocytes and centroblasts plus an admixture of nonmalignant cells such as T-
cells, follicular dendritic cells (FDCs), and macrophages [22]. FL accounts for 
approximately 20 to 25 % of NHL.  
Cytogenetically the classic finding is the t(14;18)(q32;q21) which translocates the 
BCL-2 gene located on band q21 of chromosome 18 with the Ig heavy chain (IgH) gene 
located at band 32 on chromosome 14. The translocation causes constitutive over expression 
of the BCL-2 protein as it places the BCL2 gene under the enhancers of the IgH gene. 
Overexpression of BCL-2 causes the inhibition of apoptosis in affected cells. The 
translocation though is neither necessary nor sufficient for diagnosis even though it is 
considered as the first hit mutation. The translocation is found in about 90% of FL and it is 
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Figure 4. Proposed model of the pathogenesis of follicular lymphoma. Naive B-cells carrying 
translocation t(14;18) from the bone marrow home to the B-cell follicles where they undergo the 
germinal center (GC) reaction. In the dark zone of the GC, the B-cells proliferate and are known as 
centroblasts, they undergo somatic hypermutation (SHM) and class switching of their B-cell 
receptors. Centroblasts transition to centrocytes and migrate to the light zone of the GC where they 
interact with follicular dendritic cells (FDCs) and are selected to either undergo apoptosis or rescue 
by follicular helper T-cells (TFH) based on antigen (Ag) affinity of their BCRs. Ectopic expression 
of BCL2 provides mutant B-cells with t(14;18) an avenue to escape apoptosis, independent of BCR 
affinity. These FL-like B-cells then exit the GC and enter the circulation where they might be prone 
to traffic between follicles and/or the BM and have the opportunity to acquire additional genetic 
changes necessary for transformation to FL. CSR; class switching recombination; IgM; 
immunoglobulin M; sIgM; surface immunoglobulin M. Figure adapted from Kahl, B.S. and D.T. 
Yang, 2016 [23].  
 
The Naive translocation positive B-cells then leave the bone marrow, colonize 
secondary lymphoid organs and undergo the germinal center reaction. Since they have an 
anti-apoptotic (BCL-2) mutation these cells are conferred a survival advantage [24]. 
Additional cytogenetic abnormalities do occur and are thought to be acquired in a stepwise 
fashion and these include, loss of 1p, 6q, 10q, and 17p and gains of 6p, 7, 8, 12q and 
18q/dup (Figure 4) [4, 22]. 
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 Mantle Cell Lymphoma 
Mantle cell lymphoma (MCL) accounts for 5% to 10% of all lymphoma cases in 
adults. It is derived in the vast majority of cases from a naive pre germinal center B-cell (as 
the Ig variable regions) are unmutated. MCL is characterized by cells which have an 
immunophenotypic profile similar to lymphocytes in the mantle zone or normal germinal 
follicles i.e. surface immunoglobulin (sIg)M+, (sIg)D+, CD5+, CD10-, CD43+ but typically 
do not express CD23 [4].   
At the molecular level it is defined by the translocation t(11;14)(q13;q32) which 
involves cyclin D1 (CCND1) and the IgH genes, the translocation results in cyclin D1 over 
expression (Figure 5). This over expression is thought to be essential in the pathogenesis of 
MCL. Some rare cases of MCL exist in which cyclin D1 is not overexpressed, in these cases 
cyclin D2 or cyclin D3 are usually overexpressed suggesting that deregulation of other 
members of the highly conserved cyclin family may be an alternative mechanism to cyclin 
D1 overexpression in MCL tumorigenesis. In these cyclin D1 negative cases the 
transcription factor SOX-11 is highly expressed. Since it is absent in other types of mature 
B-cell lymphoma thereby it serves as a valuable biomarker for the differential diagnosis of 
MCL in these cases (Figure 5) [25, 26]. There are 3 histological sub types of MCL; mantle 
zone, nodular or a diffuse growth pattern [27]. Two cytological variants are observed, the 
classic subtype which makes about 90% of cases and the blastoid variant which makes about 
10% of cases [28] though it has been suggested to add pleomorphic MCL and leukemic non-
nodal MCL to make 4 variants [29]. The initial event, translocation t(11;14)(q13;q32) 
occurs at the pre B cell stage of differentiation during the V(D)J segments recombination of 
the IGH variable region (IGHV) in the bone marrow. However  the tumor is composed of a 
specific population of mature B lymphocytes which indicates that the full neoplastic 
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phenotype is acquired at later stages of the B-cell differentiation process [30]. Deregulation 
of the cell cycle is the characteristic pathogenic hallmark of MCL and in connection with 
this the most important prognostic biological factor is the proliferation index or Ki67 a 
staining index with higher proliferation correlating with more adverse outcome [31]. 
 
Figure 5. Proposed model of the molecular pathogenesis during the development and 
progression of the major subtypes of MCL. Precursor naive B-cells usually with but sometimes 
without a CCND1 rearrangement colonize the inner portion of the mantle zones creating in situ 
mantle cell neoplasm. These cells already have additional molecular genetic abnormalities, such as 
inactivating ATM mutations. They may progress to classical MCL which frequently is SOX11 
positive. Finally progression to blastoid or pleomorphic MCL may occur. A smaller proportion of 
neoplastic mantle cells may undergo somatic hypermutation leading to SOX11 negative MCL. 
Figure adapted from Swerdlow et al., 2016 [29]. 
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 Multiple myeloma  
Multiple myeloma (MM) is a malignancy involving terminally differentiated plasma 
cells. The name encompasses a spectrum of plasma cell disorders ranging from monoclonal 
gammopathy of unknown significance (MGUS), a relatively benign condition, to 
smoldering MM (SMM), which is the more aggressive and symptomatic malignant disorder 
characterized by circulating myeloma cells in blood.. It is characterized by clonal plasma 
cells and in the majority of cases these cells produce monoclonal immunoglobulin or its 
fragment which subsequently has effects on organ function. All the five classes of 
immunoglobulins can be produced by multiple myeloma cells. 
Multiple myeloma is the second most frequent malignancy of the blood in the USA 
after non-Hodgkin’s lymphoma. The disease causes about 1% of neoplastic diseases and 
13% of hematological malignancies. Median age at diagnosis is about 62 years for men and 
61 years for women (range 20–92); only 2% of patients are younger than 40 years. About 
20 000 cases occur every year in the USA; the incidence adjusted for age and ethnic group is 
7.2 per 100 000 in men and 4.6 per 100 000 in women. The incidence varies globally from 1 
per 100 000 people in China, to about 4 per 100 000 people in most developed countries. 
Occurrence of the disease is more common in men than in women, and is twice as high in 
blacks as in white American people [32] [33]. The pathogenesis of multiple myeloma is 
characterized by a production of excess bone marrow plasma cells, with presence of 
monoclonal protein, resultant osteolytic bone lesions, renal disease from excess monoclonal 
protein and immune-deficiency. A multistep development model suggests that the disease 
starts from monoclonal gammopathy of undetermined clinical significance which might then 
progress to smouldering multiple myeloma, and ultimately to symptomatic intramedullary 
and extra medullary multiple myeloma, or plasma cell leukemia [34, 35]. Multiple myeloma 
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is initiated and sustained by genomic changes that provide uncontrolled proliferative 
advantages to the tumor cells. Myeloma represents the classic multistep transformation 
process with an initial premalignant stage, MGUS. It has now been well documented that all 
MM develops from MGUS, which suggests that the initial event required for transformation 
to MGUS provides the first step in a multistep process [37]. Gain, loss or translocation 
mutations on both the p and q arms of virtually all chromosomes in human has been 
documented. Even though MM has such complex mutations some recurrent mutations have 
been identified. The most prominent amongst them is hyperdiploidy of chromosomes 3, 5, 7, 
9, 11, 15, 19, or 21. Additional recurrent abnormalities include the loss of chromosome 13, 
t(4;14)(p16;q32), t(11;14)(q13;q32), or t(14;16)(q23;q32).  
The common chromosomal region involved in these translocations is the 14q32 
region, which contains the IgH gene, suggesting that this abnormality may be an early 
important event in the development of plasma cell disorders. Using FISH analysis it was 
shown that this translocation is involved in approximately 47% of MGUS patients and more 
than 70% of patients with MM. In other patients, translocation partners involve the λ light-
chain region on chromosome 22. This abnormality is observed in 17% of patients [38]. 
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Figure 6. Model of multiple myeloma cell development hypothesis. Multiple myeloma’s 
ontogeny hypothesis demonstrated by a 14q translocation positive case. During the process of 
physiological class switch recombination (CSR), double-strand breaks on the switch regions of the 
nonfunctional allele (DJH in the example) can be resolved by joining with a different chromosome 
resulting in a 14q32 translocation. If this illegitimate recombination occurs prior to legitimate CSR 
on the functional IGH allele, a mixture of different subpopulations (e.g. IgM and IgG or IgA) will 
have a survival or proliferative advantage due to the translocation, which will make them long-lived 
memory B or plasma cells without becoming fully malignant. After one of these subpopulations 
leaves the GC to become a plasma cell homing to the BM (normally IgG or IgA), secondary genetic 
hits may occur that render such cells malignant plasma cells. CSR; class switch recombination, 
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 Chronic Lymphocytic Leukemia 
It is the most common adult leukemia in the western world. Genetic factors 
contribute to the development of chronic lymphocytic leukemia (CLL); although CLL is the 
most common adult leukemia in western countries, it is less common in Asia and relatively 
rare in Japan and Korea, even among Japanese people who immigrate to western counties. It 
is characterized by clonal B-cell accumulation in the blood, the bone marrow, and the 
lymphoid tissues of affected individuals. CLL has an approximate incidence of 5 cases per 
100,000 persons in the west. It has long been regarded as an incurable disease of the elderly 
since the mean age at time of diagnosis is 65 years. It is a slow indolent disease. It will often 
remain indolent for many years even without treatment. However, many patients will 
eventually require treatment for symptoms of progressive disease such as fatigue, disease-
related fevers, increases in lymph node size and increases in spleen size and/or bone marrow 
failure due to organ infiltration with the neoplastic cells. The median survival after initiation 
of treatment is approximately 5 years [33, 37, 38].  
The major phenotypic feature of CLL is the consistent clonal expansion of CD5 
expressing B-cells [39]. The CD5+ B-cells are small and appear to be mature [40]. By 
looking at the mutational status of the immunoglobulin heavy-chain variable region gene 
(IGHV), CLL can be divided into two main subsets, these division is based on whether the 
CLL cells express an unmutated or a mutated IGHV. The status of the IGHV region reflects 
the normal stage of development from wherein the CLL arises. This division is clinically 
significant as the two subsets have differing clinical behavior and this influences treatment 
choices [41, 42]. Unmutated IGHV-CLL arises from a B-cell that has not undergone 
differentiation in germinal centers. Unmutated IGHV-CLL is a more-aggressive disease 
compared to mutated IGHV-CLL. Mutated IGHV-CLL arises from a post-germinal center B-
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cell that expresses immunoglobulin that has undergone somatic hyper mutation and, in some 
cases, also immunoglobulin isotype switching, similar to what occurs in normal B-cells 
during an immune response to antigen. 
Genetic studies have revealed various genetic alterations in CLL, and these including 
single nucleotide polymorphisms (SNPs), chromosomal alterations and microRNA 
(miRNA). Interactions between CLL cells and other cell types in their microenvironment, 
including interactions with T-cells, nurse-like cells and stromal cells, can induce B-cell 
proliferation and contribute to disease [40]. Genetic alterations in CLL can include 
chromosomal alterations, mutations, alterations in the expression of miRNAs and epigenetic 
modifications. Four chromosomal alterations are present in at least 80% of CLL cases and 
these are:  del(13q14.3) (the most common chromosomal alteration at more than 50% of 
cases), del(11q), del(17p) and trisomy 12 [43, 44]. 
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Figure 7. Pathways leading to the development of CLL cells from the naive B-cell. Chronic 
lymphocytic leukemia (CLL) cells that have unmutated IGHV apparently originate from CD5+ B-
cells prior to experiencing SHM, whereas CLL cells that have mutated IGHV most likely originate 
from CD5+ B-cells that have passed through and differentiated in the germinal center. Other CLL 
subsets include cells that have undergone immunoglobulin class-switch recombination and express 
immunoglobulin isotypes other than IgM and IgD, for example IgG or IgA or cells that express 
immunoglobulin with only minor somatic mutations. Dashed arrows indicate speculated pathways 




   19 
 
Recurrent somatic mutations have been consistently observed in genes that have a 
role in DNA damage repair (e.g. TP53 and ATM), mRNA processing (e.g. SF3B1 and 
XPO1), chromatin modification (e.g. HIST1H1E, CHD2 and ZMYM3), Wnt signaling, 
Notch signaling (for example NOTCH1) and inflammatory pathways (for example MYD88) 
[45]. The detection of somatic mutations and their relative frequencies is variable, which 
possibly reflects differences in the composition of the cohorts studied worldwide. 
Two miRNA (mir-15a and mir-16-1) alterations which have been associated with 
CLL have been found to be altered deleted or down regulated in approximately 60% of 
patients with CLL and are dysfunctional in a few cases of familial CLL. These miRNA both 
target BCL2 and MCL1 and reduced expression or loss of these miRNAs can enhance the 
expression of these target genes [46-48]. 
Various epigenetic changes have been implicated in the pathogenesis of CLL. The 
CLL epigenome has both global hypomethylation and local hypermethylation, as is the case 
in other cancers. Substantial intra-tumoral methylation heterogeneity has been revealed by 
comprehensive methylation profiling. Increasing methylation heterogeneity has consistently 
been associated with increased genetic complexity and this might enhance the evolutionary 
adaptive capacity of CLL cells by increasing the background ‘noise’ of the genome, thereby 
providing increased opportunities for somatic mutations within the leukemia clone. In 
support of this notion is the observed association between methylation evolution and 
adverse clinical outcomes [49-51].  
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 Therapeutic principles in mature B cell neoplasms treatment 
The effective and safe use of chemotherapy in the clinical settings requires a 
complete understanding of drug action, clinical toxicology, pharmacokinetics and drug 
interactions of the various agents[52]. The biggest setback however to the treatment of these 
neoplasms is the development of resistance which prevents the complete elimination of the 
neoplastic cells. Development of resistance occurs because inadequate treatment selects for 
the outgrowth of resistant tumor clones while killing the sensitive clone. The reasons for 
resistance are many, cancer cells generally have genetic mutations in DNA repair and are 
able to spontaneously generate resistant clones even before any treatment has been 
applied[52]. This is the case with imatinib mesylate resistance where imatinib resistant 
clones can be identified even before treatment in chronic myelogenous leukemia [53]. To 
top it off many drugs used for treatment are mutagenic themselves and cause mutations 
leading to drug resistance e.g. alkylating agents. After accounting for the selection of a drug 
resistant clone there is still a lot of resistance which occurs due to what is termed classical 
resistance i.e. the presence of resistance due to multi drug resistance proteins which efflux 
chemotherapeutics from the cell. Finally in addition to mechanisms of drug resistance which 
are drug specific there are mutations which target and remove the ability of cells to 
recognize DNA damage e.g. loss of the components of the mismatch repair gene complex 
which render tumors resistant to cisplatin, thiopurines or alkylating agents[54]. 
The target has therefore been to identify methods of drug resistance and ways to 
counter them and the development of new drugable targets which can be targeted to produce 
better outcomes. Examples of an effort to find explanations for resistance and ways how to 
counter it was recently published by Lorkova et al., 2015. They looked at cross resistance of 
nucleoside analogues in the treatment of MCL. MCL remains incurable; despite the fact that 
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most patients achieve either complete or partial remission after induction therapy, virtually 
all patients relapse sooner or later. The prognosis of relapsed or refractory MCL is very poor 
with no treatment standard agreed upon. Second-line treatment approaches are based on 
nucleoside analogs (fludarabine, cladribine), DNA modifying agents (bendamustine, 
cisplatin), or targeted therapeutics (bortezomib, temsirolimus, lenalidomide or ibrutinib). In 
everyday clinical practice, fludarabine-based regimens still remain important and widely 
used options for the salvage therapy of relapsed/refractory MCL [55]. Lorkova et al were 
able to show that fludarabine resistant MCL was characterized by marked downregulation of 
deoxycytidine kinase (dCK) and bruton tryrosine kinase (BTK) (thus explaining the 
observed cross-resistance to other antinucleosides and ibrutinib). They also showed that in 
resistant disease it is possible to identify new targets which make the resistant disease 
susceptible to a drug which the sensitive disease is not e.g There was upregulation of the key 
antiapoptotic protein Bcl-2 in resistant MCL clone and this was connected with markedly 
increased sensitivity to the Bcl-2-specific inhibitor ABT199 compared to fludarabine-
sensitive cells [55]. Still in MCL, Klanova et al., 2014 were able to show the same concept 
of resistance development by showing that in cytarabine (araC) resistant MCL cell lines and 
primary samples, the marked downregulation of deoxycytidine-kinase (DCK) mRNA and 
the subsequent low protein expression were the single most important molecular events. 
This finding was in all tested MCL cell lines and in 50% of the primary MCL samples. All 
the resistant clones were highly (20-1000x) cross-resistant to all the tested nucleoside 
analogs including gemcitabine, fludarabine and cladribine [56].  
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1.2 Hematopoietic stem and progenitor cells 
The hematopoietic system in humans is composed of a range of heterogeneous cells 
from the more primitive and pluripotent hematopoietic stem cells which have extensive 
proliferative and differentiation potential to the final mature cells which have limited 
proliferative and differentiation potential [57]. Using in vitro clonogenic assays that identify 
colony forming units the hematopoietic stem and progenitor cells were identified [58]. In 
humans the Lin-CD34+CD38-CD90+CD45RA- were identified as the cells with the ability of 
long term multilineage engraftment. These cells known as the hematopoietic stem cell 
(HSC) are the basis for hematopoiesis [59, 60]. During differentiation, the progeny of HSCs 
progress through various intermediate maturational stages, generating multi-potent and 
lineage-committed progenitor cells prior to reaching maturity.  
The classical model of hematopoiesis has long established that HSCs sit at the apex 
of a developmental hierarchy. In this model the self-renewing long term HSCs and short 
term HSCs progressively lose the capacity for self-renewal as they transform into short-
term, self-renewing and multipotent progenitor states. The first major lineage commitment 
occurs in multipotent progenitors, this produces progenitors that initiate the myeloid and 
lymphoid branches of hematopoiesis. From there on, within the myeloid lineage, bi-potent 
megakaryocyte-erythrocyte and granulocyte-macrophage progenitors give rise to uni-potent 
progenitors that ultimately give rise to mature progeny. On the lymphoid side , the 
multilymphoid progenitor is gives rise to mature lymphoid cells (Figure 8) [61].The 
traditional model while satisfactory has been shown not to be rigid but allows for alternate 
pathways for  mature peripheral cell production, for example with the discovery of the 
multilymphoid progenitor (MLP) which primarily gives rise to all lymphoid cell types, but 
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on top of that have the ability to develop monocytes, macrophages and dendritic cells which 
indicated that these myeloid lineages arise in early lymphoid lineage specification [61, 62]. 
 
Figure 8. Hierarchical model of hematopoiesis in the adult bone marrow. All hematopoietic 
cells ultimately derive from a small population of hematopoietic stem cells (HSCs), which can be 
divided into two subsets: long-term reconstituting HSCs (LT-HSCs) and short-term reconstituting 
HSCs (ST-HSCs). ST-HSCs derive from LT-HSCs and, although they maintain multipotency, they 
exhibit more-limited self-renewal potential. Further differentiation of ST-HSCs generates 
multipotent progenitors (MPPs) and then oligopotent progenitors, which are marked with asterisks. 
Hematopoietic progenitor cells lose their differentiation potential in a stepwise fashion until they 
eventually generate all of the mature cells of the blood system (depicted at the bottom of the 
schematic). Several potentially distinct subsets of MPPs have been described, but MPPs are shown 
here as a condensed population for simplicity. Lineage-committed oligopotent progenitors derived 
from MPPs include the common lymphoid progenitor (CLP), common myeloid progenitor (CMP), 
megakaryocyte-erythrocyte progenitor (MEP) and granulocyte-monocyte progenitor (GMP) 
populations. NK; natural killer, SCA1; surface cell antigen 1. Figure adapted from Wang, L.D. and 
A.J. Wagers, 2011 [63]. 
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The second example is the observation that megakaryocytes can be generated from multiple 
pathways and that some differentiation pathways do not require transit through a requisite 
multipotent or bi-potent megakaryocyte-erythrocyte progenitor stage. In this alternative 
model, upon loss of megakaryocyte and erythroid potential, pluripotent HSCs develops into 
lymphoid primed multipotent progenitors (LMPP) that upon loss of granulocyte monocyte 
potential generate the CLP [64].  
 Hematopoietic stem cell 
Hematopoietic stem cells (HSC) in the human have to satisfy two conditions; they 
have to be self-renewing and they should also have the ability to differentiate into all the 
different blood cells. HSC reside at the top of hematopoietic hierachy (Figure 8). Previously 
HSCs were primarily identified and enriched using CD34+ surface expression [65]. By using 
a stringent two-step strategy involving depletion of lineage-positive cells followed by 
fluorescence-activated cell sorting, Bhatia et al., 1997 were able to purify HSC cells in the 
Lin- CD34+CD38- fraction. This purified cell population was highly enriched for cells 
capable of multilineage repopulation in non-obese diabetic/severe combined 
immunodeficient (NOD/SCID) recipients [66]. Majeti et al., 2007 were subsequently able to 
show that the human HSC can be identified by flow cytometry and it was in the Lin-
CD34+CD38-CD90+CD45RA- compartment [60]. 
 Multipotent progenitor cells 
Multipotent progenitors are a class of hematopoietic stem cells that have lost their 
self-renewal capacity and as such are not exactly stem cells but remain multipotent and thus 
can differentiate into all mature cell types found in the blood. Current understanding divides 
them into the common lymphoid progenitors which can give rise to T, B, NK cells and the 
common myeloid progenitor which gives rise to the myeloid line of cells (Figure 8) [67, 68]. 
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Various other types of multipotent progenitors have been proposed which fall out of the 
classical model [64], Majeti et al., 2007 using in vitro methylcellulose and mouse 
xenotransplantation assays described a multipotent progenitor which was able to give rise to 
itself and another progenitor which is downstream of it using CD34, CD38, CD90 and 
CD45RA as discriminators. This multipotent progenitor (Lin-CD34+CD38-CD90-CD45RA-) 
was not able to give rise to HSCs (Lin-CD34+CD38-CD90+CD45RA-) but was able to give 
rise to itself and to a supposedly lower ranked progenitor (Lin-CD34+CD38-
CD90+CD45RA+) [69]. 
 Multilymphoid progenitor cells 
The multilymphoid progenitor cell (MLP) is one of the progenitors which currently 
do not abide by the classical model as it is able to give rise to lymphoid cells but also to 
some cells (but not all) from the myeloid progenitor cell. Various markers have been used to 
describe this progenitor cell [64, 70]. Using colony forming assays Doulatov et al., 2010 
isolated seven distinct progenitor classes from cord blood and bone marrow samples using a 
single panel of seven markers. They investigated their developmental potential using clonal 
analysis under conditions that provided robust support of multiple lineage lines. Using such 
a comprehensive method they identified human MLPs as a distinct CD90loCD45RA+ 
population in the CD34+CD38− HSC compartment. The MLPs were able to generate all 
lymphoid cell types, as well as monocytes, macrophages and dendritic cells [62]. Other 
studies have described MLPs with B-cell, T-cell and NK cell potential and have placed them 
in the CD10+CD24− or CD38−CD7+ fraction [70, 71]. 
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 Pro B-cell 
The earliest precursor committed to the B-cell lineage is the pro B cell. It is a rapidly 
proliferating cell which is CD19+ CD117+ and has its IgH D–J genes rearranged [72-74]. 
Lymphoid progenitor cells under the influence of cytokines then initiate B-cell 
development. Cytokines induce terminal deoxynucleotidyl transferase (TdT) and 
recombinase (RAG-1 and RAG-2) synthesis in CD34+ lymphoid progenitors. The cells 
undergo diversity-junction joining on the H chain chromosome (D-JH) to become early pro 
B cells, they also begin to express CD45 and class II major histocompatibility complex. 
Joining of a V segment to the D-JH completes the transition to late pro B cell stage. Pro B 
cells progress along the developmental chain and become pre B cells when they express 
membrane m chains with surrogate light chains in the pre B receptor. The pre B cell finally 
gives rise to the naïve mature B-cell. 
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2 HYPOTHESIS AND THE AIMS OF THE STUDY 
Mature B-cell neoplasm arises from the various stages of peripheral B-cell 
development beginning with CLL (from mature naive B-cells), DLBCL, FL, CLL (from 
germinal center B-cells), MCL (from the mantle zone), multiple myeloma and MGUS 
(plasma cell). Recently however several authors have suggested that origins of mature B-cell 
neoplasms might be found already at the level of hematopoietic stem cells and that the 
presence of malignant disease has an effect on normal hematopoiesis [10-14]. The 
proportions of HSPCs and their gene expressions in untreated patients with mature B cell 
neoplasms has not been extensively studied. Based on the current state of knowledge and 
currently existing scientific reports we hypothesize that the presence of malignancy has an 
effect on the status of hematopoiesis in patients in mature B-cell neoplasms. 
It is our aim to: 
• Determine the correlation of age with hematopoietic stem and progenitor cells 
proportions in healthy subjects in order to confirm or contradict existing reports. 
• Explore if there are any changes to correlation patterns (age versus hematopoietic 
stem and progenitor cell proportions) observed in healthy controls when the same 
analysis is done on patients with mature B-cell neoplasms. 
• Determine if there is a difference between the proportions of hematopoietic stem and 
progenitor populations in patients with mature B-cell neoplasm when compared to 
healthy controls.  
• Determine if the presence of infiltration by malignant cells has any effect of any 
deregulation that might be present. 
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• Explore gene expression of select genes to elucidate if the transcriptional program of 
patients hematopoietic stem cells is altered when compared to healthy hematopoietic 
stem cells. 
• Look for evidence of humoral factors, secreted by malignant cells or influenced by 
their presence, which might be involved in gene expression changes in hematopoietic 
stem cells. 
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3 MATERIALS AND METHODS 
3.1 Materials 
 Chemicals and kits 
Annexin V FITC and PE conjugated (Apronex Biotechnologies) 
EDTA (ethylenediaminetetraacetic acid) (Sigma-Aldrich) 
Fetal bovine serum (FBS) (Lonza) 
Ficoll-Paque (GE Healthcare) 
Iscove’s Modified Dulbecco’s Medium (IMDM) (Lonza) 
Phosphate buffered saline (PBS) (Amresco) 
Propidium iodide (Sigma-Aldrich) 
TaqMan® Universal Master Mix II (Life Technologies) 
CellsDirect™ One-Step qRT-PCR Kit (Invitrogen)  
Flebogamma IVIG (Grifols Biologicals Inc) 
 Antibodies 
Lineage Cell Detection Cocktail-Biotin (Miltenyi Biotec) 
Streptavidin-APC-Cy7 (Biolegend) 
CD34-PE, 8G12 (Biolegend) 
CD38-PE-Cy7, HIT2 (Biolegend) 
CD90-FITC, GE10 (eBioscience) 
CD45RA-APC, HI100 (eBioscience) 
CD19-FITC, HIB19 (eBioscience) 
CD10-APC, CB-Calla (eBioscience) 
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 TaqMan® Gene Expression Assays 
All bought from Life Technologies 
ABCB1 Hs00184500_m1 
BCL11A Hs01093197_m1 
BCL2  Hs00608023_m1 
BCL2L1 Hs00236329_m1 
BCL6  Hs00153368_m1 
BMI-1  Hs00995536_m1 
CCND1 Hs00765553_m1 
CD10   Hs00153510_m1 
CD19  Hs00174333_m1 
CD20  Hs00544819_m1 
CD31  Hs00169777_m1 
CD34  Hs00990732_m1 
CD38   Hs01120071_m1 
CD44  Hs01075861_m1 
CD5  Hs00204397_m1 
CD79A Hs00998119_m1 
DNTT  Hs00172734_m1 
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IKAROS Hs00958474_m1 
IRF4  Hs01056533_m1 
IRF8  Hs01128710_m1 
LEF1  Hs01547250_m1 
MALT1 Hs01120052_m1 
MCL1  Hs01050896_m1 
MYC  Hs00153408_m1 
NOTCH1  Hs01062014_m1 
PAX5  Hs00172003_m1 
PRDMI Hs00153357_m1 
PROM1 Hs01009250_m1 
PU.1   Hs02786711_m1 
RUNX1  Hs00231079_m1 
SOX11 Hs00846583_s1 
SOX4  Hs00268388_s1 
ZAP70  Hs00896347_m1 
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 Bone marrow samples  
Between 28th February 2012 and 24th April 2015 125 bone marrow samples from 
newly diagnosed and untreated patients with mature B-cell malignancies (Table 1). Samples 
collected included CLL (n=21, median age 66, range 40-79), MCL (n=27, median age 65, 
range 48-79), DLBCL (n=35, median age 65, range 29-81), FL (n=24, median age 63, range 
40-82), and MM (n=18, median age 65, range 30-73). 
22 BM samples were obtained from healthy volunteers. From these, 13 age-matched 
(median age=63 years, range 29-78 years) BM samples were used for comparison to the 
whole PT cohort (n=125, median age 65 years, range 29-82). 15 age-matched (median age 
27 years, range 22-45) BM samples were used for comparison to the younger patients (i.e. 
<45 years), and 7 age-matched (median age 70 years, range 63-78) BM samples were used 
for comparison to the elderly patients (≥45 years) (Table 1). All the material was obtained 
after full informed consent was obtained per the guidelines of the Helsinki Declaration of 
1975 that was revised in 1985 and after approval by the Ethics Committee of the Charles 
University General Hospital in Prague. Additionally 6 Caucasian and 4 Asian bone marrow 
samples were obtained from Allcells, LLC, USA. 
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Table 1. Summary of analyzed Patients and control samples. Disease characteristics. Diagnostic, 
prognostic and clinical features of the patients is shown. CLL; Chronic lymphocytic leukemia, 
DLBCL; diffuse large B cell lymphoma, MCL; mantle cell lymphoma, MM; multiple myeloma, FL; 
follicular lymphoma, IPI; international prognostic index, MIPI; Mantle Cell Lymphoma 
International Prognostic Index, ISS; International Staging System, FLIPI; Follicular Lymphoma 
International Prognostic Index. 
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3.2 Methods 
 Sample collection and processing 
Samples were freshly obtained by Trephine biopsy from the posterior iliac crest and 
mononuclear cells were immediately concentrated by ficoll-hypaque gradient centrifugation 
methods. Cells were then twice washed in PBS and incubated with 1% intravenous 
immunoglobulin (IVIG) at room temp for 10 minutes and then stained with relevant 
antibody cocktails ready for flow cytometry analysis and fluorescence activated cell sorting 
(FACS). 
 Antibodies, Cell Staining, sorting and storage 
Human HSPCs namely; hematopoietic stem cells (HSC) which are lineage-
CD34+CD38-CD90+CD45RA,- multi-potent progenitors (MPP) which are Lin-CD34+CD38-
CD90-CD45RA-, multi-lymphoid progenitors (MLP) which are Lin-CD34+CD38-CD90-
CD45RA+, and pro B cells which are CD34+CD38+CD10+CD19+ were stained and 
subsequently measured and sorted using a FACS Aria IIu, BD Biosciences) and evaluated 
using BD Facs Diva 6 software [12, 69, 75, 76]. For the isolation of HSC, MPP and MLP 
the concentrated mononuclear cells were stained with a biotinylated lineage positive 
antibody cocktail (Miltenyi Biotec) and for visualization were secondarily conjugated with 
APC-Cy7 streptavidin (Biolegend, Fell, Germany) to exclude lineage positive cells. Cells 
were further stained with PE-anti-CD34 (clone 8G12), Pe-Cy7-anti-CD38 (clone HIT2), 
FITC-anti-CD90 (clone eBio5E10) and APC-anti-CD45 (clone HI100). For the isolation of 
the Pro B population the cells were stained with PE-anti-CD34 (clone 8G12), Pe-Cy7-anti-
CD38 (clone HIT2), FITC-anti-CD19 (clone HIB19), and APC-anti-CD10 (LT10).  
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Relevant isotype matched controls and fluorescence minus one controls were used to 
determine the level of background staining. Exclusion of non-viable cells was done using 
propidium iodide (PI) staining. Gating scheme for the identification of described 
populations is shown in below (Figure 9). The sorted cells then underwent a second round of 
sorting for purity using the same gates from first round. The Appropriate number of cells 
were then sorted directly into CellsDirect One-Step qRT-PCR cells lysis solution 
(Invitrogen) and stored at -80°C pending specific target amplification (STA).  
 
Figure 9. Flow cytometry gating scheme for identifying BM-derived HSPC populations. A 
representative gating strategy for: (A) HSC, MPP and MLP analysis in CTRL samples (top) and PT 
samples (bottom), (B) pro B analysis for CTRL samples (top) and PT samples (bottom). After dead 
cells and lineage positive cells were excluded the various hematopoietic stem and progenitor cells 
(HSPCs) were analyzed and only HSC was sorted into storage media for later gene expression 
experiments. HSC; hematopoietic stem cell, MPP; multipotent progenitors, MLP; multilymphoid 
progenitors, BMMC; bone marrow mononuclear cell. 
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 Specific Target Amplification  
Pooled TaqMan assays were first prepared by mixing all the primers in one tube and 
diluting with Tris-EDTA (TE) buffer so that each assay had final concentration of 0.2X. 
Before quantitative real-time PCR analysis, pro B or HSC cells underwent specific target 
amplification thusly; 2 µL of lysate solution (corresponding to 100 lysed cells) was 
combined with 0.2X pooled TaqMan assays mix (Applied Biosystems) 2X reaction mix 
(CellsdirectTM, Invitrogen) and Superscript III/Platinum Taq mix (Invitrogen) [77]. The 
final volume for STA was 20 µL. Samples were then run on a Mastercycler Gradient 
(Eppendorf) with temperature settings 50°C for 15 minutes for reverse transcription (RT), 
then 2 minutes at 95°C after RT. STA was carried out with 14 cycles of 95°C for 15 seconds 
and 60°C for 4 minutes. The STA product was then diluted with TE buffer 1:5 to final 
volume of 100 µL and stored at -8°C till next step [78, 79]. 
 Real-time qPCR  
Real-time qPCR was done on an ABI 7900HT Fast Real-Time PCR System (Life 
Technologies) with human GAPDH as an internal control. TaqMan gene expression assays 
for all the genes analyzed were from Life technologies. All sample amplifications were done 
in 8 µL volumes and were done in duplicates.The data was analyzed using SDS 2.4 software 
(Applied Biosystems) using the comparative Ct method and data were displayed as mean ± 
standard deviation (SD). Statistical significance of differences between samples was 
evaluated using students t-test using GraphPad Prism software version 5 and P values less 
than 0.05 were considered statistically significant (* P < 0.05, **P < 0.01, ***P < 0.001). 
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 Serum incubation  
40 million healthy donor BMMCs after Ficoll separation were incubated for 24 hours 
in either 4 mL of serum obtained from untreated newly diagnosed patients with MCL and 
DLBCL, as control healthy donor serum from same cell PBMC donor was used. After 24 
hours the cells were washed of the serum with a PBS+1% IVIG solution and stained for 
HSPC populations, cell sorting was done on FACS Aria IIu by sorting 2000 cells into 25 µL 
of lysis buffer and STA and real time qPCR performed as already explained. 
 General Statistical analysis  
Statistical significance of differences between sample means was evaluated using 
Student´s t-test and mean ± SD was reported. Correlation analysis with 95% confidence 
interval was done and all linear regression analyses show the 95% confidence of the best fit 
line. All statistical analyses were done on Prism software (Version 5, GraphPad Software). 
P-values <0.05 were considered statistically significant. 
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4 RESULTS 
4.1 Correlation of the absolute and relative hematopoietic stem and 
progenitor cell populations in healthy controls with age. 
Studies have shown that as people age their hematopoietic stem cells change. Studies 
in children (1-17 years) have shown that there is correlation of nucleated cell count, CD34+ 
cell percentage and CFU-GM colonies with age. The proportion of the nucleated cell, the 
percentage of CD34+ cells, and colony forming unit granulocyte-monocyte counts were all 
found to decrease with age with no sex bias [80]. While most studies focus on the CD34+ 
cells compartment recently Kuranda et al., 2011 have shown much deeper analysis of the 
HSC precursor compartment by analyzing also the changes of HSC together with MPP and 
MLP. They were able to show that HSPCs undergo quantitative changes with increasing age 
[15]. In our present study, we confirmed the age-related changes observed by Kuranda et al., 
2010.  
From the absolute numbers of control HSPCs (i.e. from all measured BMMC) only 
CTRL-HSC did not significantly change with age (r=0.007, P=0.97) (Figure 10A). The 
absolute CTRL-MPP (r=0.54, P=0.01) and absolute CTRL-MLP (r=0.74, P˂0.0001) both 
showed a tendency to increase as age increased (Figure 10B, C). The most significant 
association with age was with CTR-MLP (Figure 10C). The absolute CTRL-pro B 




Figure 10. Correlation of hematopoietic stem and progenitor cells with age in healthy controls. Age-related changes of absolute (A-D) and relative 
(E-H) numbers of hematopoietic stem and progenitor cells (HSPC) populations in the BM-derived samples obtained from healthy controls (CTRL) 
(n=22). Linear regression analysis demonstrates correlation of HSPC frequencies with age. Pearson´s correlation coefficients (r), and P-values are 
shown. HSC: hematopoietic stem cell; MPP: multipotent progenitors; MLP: multilymphoid progenitors; BMMC: bone marrow mononuclear cell. 
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The relative numbers (when evaluating HSPCs as a fraction of the Lineage-
CD34+CD38- BMMC population) were also evaluated. CTRL-HSC showed a negative 
correlation with age which was significant (r=-0.57, P=0.005) (Figure 10E). Relative 
CTRL-MPP did not show significant correlation with age (r=0.14, P=0.54) (Figure 10F) but 
the relative CTRL-MLP showed concordance with the absolute values by having positive 
correlation with increasing age (r=0.74, P˂0.001) (Figure 10G), with this correlation being 
also the most significant. Relative CTRL-pro B negatively correlated with age and once 
again this correlation was statistically significant (r=-0.43, P=0.04) (Figure 10H). 
4.2  Correlation of HSPC populations frequencies with age in patients 
with mature B cell neoplasms 
Analysis of patients’ samples revealed that both the absolute PT-HSC (r=-0.12, 
P=0.17) and relative PT-HSC (r=-0.005, P=0.95) populations did not correlate at all with 
age meaning that the negative correlation seen in relative CTRL-HSC was lost (Figure 11A, 
E and Figure 10E). The PT-MPP showed no correlation with age both as relative and as 
absolute numbers (r=0.12, P=0.15 and r=0.14, P=0.54) respectively (Figure 11B, F). The 
most dramatic divergence between patients and healthy subjects was found in MLP where 
the positive correlation that was exhibited by both the relative and absolute CTRL-MLP 
numbers (Figure 10C, G) was completely lost in PT-MLP. The absolute PT-MLP showed 
no significant correlation with age (r=-0.09, P=0.27) and the same was observed in the 
relative PT-MLP (r=-0.13, P=0.13) (Figure 11C, G). The absolute PT-pro B showed 
concordance with the observed changes in CTRL-pro B by displaying negative correlation 
with age (r=-0.30 P=0.006). Relative CTRL-pro B negatively correlated with age and once 




Figure 11. Correlation of hematopoietic stem and progenitor cells with age in patient samples. Age-related changes of absolute (A-D) and relative 
(E-H) numbers of hematopoietic stem and progenitor cells (HSPC) populations in the BM-derived samples obtained from Patients (PT) samples before 
treatment (n=125). Linear regression analysis demonstrates correlation of HSPC frequencies with age. Pearson´s correlation coefficients (r), and P-




The absolute PT-pro B showed concordance with the observed changes in CTRL-pro 
B by displaying positive correlation with age (r=-0.30 P=0.006). Relative CTRL-pro B 
negatively correlated with age and once again this correlation was significant (r=-0.23, 
P=0.01) (Figure 11D, H). 
4.3 HSPC frequency deregulation in older patients compared to younger 
patients 
The PT samples were then divided into two groups in order to investigate the presence 
of age bias in our data. The first group was of PT ≤45 years (n=11, median age 27 years) 
and the second group was of PT older than 45 years (n=71, median age 70 years). 15 healthy 
BM samples were age-matched to the younger PT (i.e. ≤45 years), and 7 healthy BM 
samples were age-matched to the elderly PT (>45 years). The absolute percent of HSCs and 
MPPs in both the younger and older cohorts did not show any significant differences when 
compared to their age matched controls (Figure 12 A, B). The MLP populations of the 
younger patients did not show any significant differences when compared to their 
corresponding age matched young controls, in contrast to the older patients who had 
significantly lower absolute MLP when compared to their age matched controls 
(0.04±0.05% vs. 0.22±0.13%, P˂0.0001) (Figure 12C). The absolute pro B population did 




Figure 12. Comparison of hematopoietic stem and progenitor cells between younger and older patients. Patients divided into elderly (>45 years) 
and younger groups (≤45) and compared. Absolute values are shown for hematopoietic Stem and progenitor cell (HSPC) (A-B) and relative values are 
shown in panels (E-H). Means and standard deviations together with Student’s t-test P-values are shown at the top of the paired columns. ns: not 




We then analyzed the relative frequencies and by comparing younger patients to 
younger age matched controls and older patients to age matched older controls. The relative 
PT-HSC frequencies of younger patients were not significantly different from the younger 
controls but the relative HSC frequencies of the older patients were significantly higher than 
their age matched controls (43.79±15.88 vs. 26.52±9.13; P˂0.005) (Figure 12E). Both the 
older and younger patients did not show any significant differences in their relative MPP 
when compared to their age matched controls (Figure 12F). Younger Patients did not show 
any difference from their controls in relative MLP frequencies but the older patients had 
significantly lower relative MLP frequencies when compared to their age matched controls 
(7.67±6.67 vs.27.27±5.09; P˂0.0001) (Figure 12G). The relative pro B frequencies were the 
only HSPC to show significant differences between younger controls and younger patients 
(39.91±16.49 vs. 20.37±13.67; P˂0.01). No significant differences between the older PT-
pro B patients and the older CTRL-pro B were found (Figure 12H). 
4.4 Frequencies of HSPC populations in patients compared to controls 
 We analyzed HSPC changes in the whole PT cohort (n=125) compared to age 
matched CTRLs (n=13) and in addition a sub analysis of all infiltrated samples versus 
CTRLs and all uninfiltrated samples versus CTRLs was also done (Figure 13). It was 
evident that the absolute numbers of HSC were not significantly different between the PT 
samples and CTRL samples (Figure 13A), but there was a statistically significant increased 
relative numbers of PT-HSC (44.4 ± 16.8% in PTs versus 33.5± 14.9% in CTRLs, P=0.02) 
The increased relative PT-HSC was present in both infiltrated and uninfiltrated samples and 
in both cases the increase was significantly high when compared to CTRL-HSC (Figure 
13E).  
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While the absolute numbers of PT-MPP were significantly decreased compared to 
controls (0.189 ± 0.206% in PTs versus 0.349 ± 0.081% in CTRLs, P=0.01) (Figure 13B), 
the relative numbers of PT-MPP were not changed compared to CTRL-MPP (Figure 13F). 
Both the infiltrated and uninfiltrated PT-MPP were not significantly different from CTL-
MPP.  
The most changed population was the MLP population. Both the absolute and 
relative numbers of MLP were significantly decreased in PTs compared to CTRLs: 0.0432% 
± 0.0552 versus 0.142% ± 0.137 (p<0.0001), and 7.79 ± 6.58 versus 18.32 ± 11.38 
(p<0.0001), respectively (Figure 13 C, G) The infiltrated and uninfiltrated subanalysis of 
PT-MLP showed that both infiltrated and uninfiltrated samples had concordance with the 
whole PT-MLP cohort analysis i.e. they were both significantly lower when compared to 
CTRL-MLP (Figure 13C, G). Finally we analyzed pro B populations, both the absolute and 
relative numbers of PT-pro B cells were not significantly different when compared to PT-
CTRL (Figure 13D, H). The infiltrated and uninfiltrated PT-pro B we concordant with the 





Figure 13. Analysis of hematopoietic stem and progenitor cell frequencies between age-matched controls and the whole patient cohort. Patients 
samples are shown as a whole cohort of both infiltrated and non-infiltrated samples (PT) and division of all patients into infiltrated and uninfiltrated 
age-matched control samples were used.  P-values of unpaired Student’s t-tests are shown at the top of each column. Means and standard deviations are 
graphically expressed. ns: not significant; HSC: hematopoietic stem cell; MPP: multipotent progenitors; MLP: multilymphoid progenitors; BMMC: 
bone marrow mononuclear cell; PT: patient; CTRL: control. 
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4.5 Frequencies of HSPCs in the individual diagnoses of mature B-cell 
malignancies compared to CTRLs 
Mature B cell malignancies are a diverse group and as such we analyzed them 
separately and compared each disease individually to the CTRL cohort to elucidate if there 
were differences between diseases in terms of HSPC deregulation (Figure 14). The absolute 
numbers of HSCs were not significantly different from CTRLs in any of the analyzed 
subtypes of B-cell malignancies, though the CLL-HSCs showed a trend toward a decrease 
compared to CTRLs (P=0.09) (Figure 14A). The absolute numbers of MPP were 
significantly lower compared to CTRL in all the analyzed B-cell malignancies except 
DLBCL (Figure 14B). The absolute numbers of MLP were significantly decreased 
compared to CTRL-MLP, and this decrease was present in all the diagnoses (Figure 14C). 
In the pro B comparison only CLL pro B were significantly lower than CTRL pro B, all the 
other diagnoses were not significantly different (Figure 14D.) 
We next looked at the relative HSPC proportions. Relative numbers of HSC were 
significantly increased in 3 of the diagnosis (FL, DLBCL and MCL) but the increase was 
not significant in the CLL and MM patient cohorts (although there was a trend toward 
increased numbers in MM, P=0.0561) (Figure 14E). The relative numbers of MPP were 
decreased in FL (P=0.05) and increased in CLL (P=0.05) compared to CTRL, while in 
DLBCL, MCL and MM no significant changes were observed (Figure 14F). The relative 
frequencies of MLP in PT samples were significantly lower in all the diagnosis when 
compared to CTRLs (Figure 14G). The relative pro B frequencies were significantly 




Figure 14. Comparison of individual diagnosis with healthy control samples. Whole patient cohort was subdivided into its component mature B cell 
neoplasms and each compared to controls. P-values of unpaired Student’s t-tests are shown at the top of each column. Means and standard deviations 
are graphically expressed. ns: not significant; HSC: hematopoietic stem cell; MPP: multipotent progenitors; MLP: multilymphoid progenitors; BMMC: 
bone marrow mononuclear cell; PT: patient; CTRL: control; FL: follicular lymphoma; DLBCL: diffuse large B-cell lymphoma; MCL: mantle cell 
lymphoma; CLL: chronic lymphocytic leukemia; MM: multiple myeloma. 
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4.6 Correlation of bone marrow infiltration with absolute and relative 
HSPC proportions. 
We further analyzed, whether the detected changes in the absolute and/or relative 
numbers of HSPC might be associated with the extent of BM infiltration by neoplastic cells. 
From the 125 patient samples 77 (61.6%) patients had detectable BM infiltration by 
immunohistochemical (IHC) analysis of trephine biopsy specimens. The infiltration extent 
ranged from 2.5% to close to 100% and the median infiltration extent was 40% (Figure 15A, 
B). The absolute numbers of all analyzed populations of HSPCs negatively correlated 
(significantly with exception of HSC) with the extent of BM involvement (Figure 15C-F). 
While the relative numbers of PT-HSC (r=-0.25, P=0.02) and PT-MLP (r=-0.41, P=0.002) 
(Figure 15 G, I) demonstrated negative correlation with BM infiltration, relative numbers of 
PT-MPP (r=0.40, P=0.003) showed positive correlation with the extent of infiltration 
(Figure 15H). There was no significant correlation between relative numbers of pro B and 





Figure 15. Correlation of infiltration extent with hematopoietic stem and progenitor cell frequencies. Overview of the extent of BM involvement per 
diagnosis (A, B) and correlation of absolute (C-F) and relative (G-J) HSPC frequencies with the extent of BM infiltration in patient samples with detectable 
BM infiltration. Pearson's correlation coefficients (r), and P-values are shown. HSC: hematopoietic stem cell; MPP: multipotent progenitors; MLP: 
multilymphoid progenitors; BMMC: bone marrow mononuclear cell; FL: follicular lymphoma; DLBCL: diffuse large B-cell lymphoma; MCL: mantle cell 
lymphoma; CLL: chronic lymphocytic leukemia; MM: multiple myeloma; IHC: immunohistochemistry. 
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4.7 Gene expression analysis of HSCs for differential expression of key 
regulators of hematopoiesis and select proto-oncogenes.  
To try to understand if there were genetic factors involved in the deregulation of 
gene expression we analyzed expression patterns of 27 genes which included HSC, B-cell / 
T-cell transcription factors, and established proto-oncogenes, GAPDH was used as an 
internal control. Gene expression analysis was carried out on 63 PT samples (MCL: n=16; 
FL: n=13, DLBCL: n=15, CLL: n=7 and MM: n=12) and 13 CTRL samples. We considered 
a particular gene to be expressed in the PT or CTRL cohorts only if its transcription was 
detectable after 40 cycles of qPCR in more than 25% of the particular samples. Using this 
criterion we observed 3 groups of gene expression patterns in HSC samples. According to 
gene expression frequencies we divided the genes into groups. The first group (group 1) 
consisted of genes expressed in >25% of all cases (i.e. in both CTRL and PT) (Figure 16). 
This group was further divided into 2 subgroups. The first subgroup (group 1a) comprised of 
genes with significantly different relative mRNA expression in PTs compared to CTRLs. 
Curiously, all the group 1a genes showed significantly higher expression levels in PTs 
compared to CTRLs and none showed significantly reduced expression (Figure 16). The 
second subgroup (group 1b) genes were not significantly differently expressed between 
CTRLs and PTs. Group 2 consisted of genes expressed in PT, but not CTRL. It must be 
noted that a third group (group 3) which comprised of genes with undetectable expression 
(neither in CTRL nor in PT) existed and included LEF1, EBF1, BCL2, MALT1, BCL6, 
IRF4, and PRDM1 (data not shown). Not a single gene was expressed exclusively in CTRL 
(but not in PT) samples. 
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Figure 16. Gene expression analysis from sorted patient-HSC. Sorted HSCs from the various 
diagnoses were analyzed for the expression of various genes, The proportion of samples from PT 
cohort and CTRL samples is shown together with the relative amount of gene expression and the P-
value of student’s T test (A). Heat map analysis of gene expression in the various diagnoses is shown 
to highlight differences in gene expression between the diagnosis and within the selected genes (B). 
Comparative Ct method was used and Student’s t-test was used for comparison, P values are shown. 
CTRL: Control; PT: patient; MCL: Mantle cell lymphoma; DLBCL: Diffuse large B/cell lymphoma; 
FL: Follicular lymphoma; CLL: Chronic lymphocytic leukemia; HSC: Hematopoietic stem cell; 
S.D.: Standard deviation. 
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4.8 Functional serological analysis for evidence of tumor released 
humoral factors which can affect gene expression. 
To elucidate if in the serum of patients with mature B-cells neoplasms contained any 
humoral factor/s, which could provide the driving force behind the observed deregulations, a 
functional experiment was done. PBMC cells from a healthy donor were incubated in cell 
free serum from untreated patients (MCL and DLBCL) overnight, gene expression as 
previously described was carried out 24 hours later. From the 5 representative genes chosen 
it is evident that DLBCL serum induced detectable changes in the gene expression of 
IKAROS, GATA2, RUNX1 and MYC genes. As control, healthy serum was used to incubate 
the same CTRL cells. The changes observed with DLBCL serum were not observed with the 









Figure 17. Serum incubation experiment to elucidate presence of molecular mediators’ released into the blood of patients with mature B-cell 
neoplasms. Healthy peripheral blood monocytes were incubated 18 hours in the presence of serum from a healthy donor and serum from a patient diagnosed 
with MCL and DLBCL. Gene expression was perfomed and results expressed as fold change plus range. CTRL: Control; MCL: mantle cell lymphoma; 




4.9 Early B cell hematopoeis might have differences which are influenced 
by ethnicity and this might reflect on incidence of CLL 
We studied the pro B cell population further by simultaneously comparing the mean 
percentages of pro B cells in the BM of patients with CLL with two different types of 
controls; healthy Caucasians and healthy Asians. CLL was chosen due to the fact that the 
incidence of CLL is much more common in Caucasians (20X) compared to Asians who 
have relatively low incidence [81]. The other reason was the fact that recent reports suggest 
that CLL is a mature B cell lymphoma where the propensity to develop clonal B cells is 
already acquired at the HSC level [10]. The mean percentage of pro B cells in healthy 
Caucasians (n=29) was 29.2 ± 3.2% and the mean percentage in healthy Asians (n = 5) was 
12.1 ±2.6%. (Figure 18). Both figures were significantly different from the mean percentage 
of pro B in CLL (n = 21) which was 21.2 ± 3.4%, though it must be noted that Asians had 
significantly lower pro B percentage and causcasians had significantly higher pro B 
percentage (Figure 18). The percentages of proB cells in CLL patients corresponded to those 
reported by Kikushige et al. Our data (in combination with those of Kikushige et al.) thus 
demonstrate statistically significant differences in relative numbers of proB cells in the BM 
of healthy Asians (low) compared to Caucasians (high) and this might be an explanation for 
the much more reduced incidence of CLL in Asians compared to the Caucasian population. 
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Figure 18 Frequencies of proB cells in healthy Caucasians, Asians, and patients (Caucasians) 
with CLL. Asterisks denote mean percentages of proB cells obtained by Kikushige et al. [10]in 
healthy controls (*) and CLL patients (**). Lines are plotted at means. CTRL-C; Control 
Caucasians, CTR-A; control Asians, CLL; chronic lymphocytic leukemia. Figure adopted from 





The mature B-cell malignancies are one of the most common types of hematologic 
tumors. Despite this there is not much information available on the composition and 
function of hematopoiesis in patients with these malignancies. Hematopoietic stem and 
progenitor cells might be influenced by at least three key factors: the first being HSPC 
intrinsic mutations (that might predispose subjects to the development of these 
malignancies), secondly the presence of malignant lymphocytes in the bone marrow or extra 
medullary tissue which may directly or indirectly impact HSPCs through various 
mechanisms and lastly age-related changes as subjects get older and their hematopoiesis 
changes as part of the general aging process [10, 11, 13, 14, 83-86].  
In this study we focused on complex flow cytometry and gene expression analysis of 
selected BM-derived HSPC populations obtained from patients with mature B-cell 
malignances before initiation of therapy. We observed significant differences in both 
absolute and relative HSPC numbers, as well as in HSC gene expression between PT 
samples and healthy volunteers. Observed differences between pro B cell populations from 
healthy controls of different ethnicities may also explain the differences in incidence of 
some mature B cell lymphomas between different ethnicities. 
It was repeatedly shown that HSPC do undergo quantitative and functional changes 
with age, for example while in the pediatric age group the numbers of CD34+ cells decrease 
with age, several works have shown that the bone marrow derived HSC are more numerous 
in the elderly compared to younger individuals, in addition to this the proportions of the 
more matured B lymphoid progenitors were found to be decreased in elderly patients [12, 
15, 80]. 
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As such we first analyzed the correlation of age with HSPC frequencies in the bone 
marrow of healthy volunteers (n=22). As we have recently shown that healthy Caucasians 
have significantly higher bone marrow pro B cells compared to Asians (and this might have 
effect on the incidence of CLL in the various groups) we used a control group that was 
caucasian as our patients were caucasian as well. To avoid any potential age bias all 
comparisons were done using appropriate age matched controls [82]. Our analysis 
confirmed the age related changes reported by Kuranda et al., 2011 i.e. increased absolute 
HSC, MPP and MLP in older CTRL samples compared to younger ones though it should be 
noted that the positive correlation of all three populations with age was statistically 
significant only in the MPP and MLP populations. On the other hand the relative CTRL-
HSC populations significantly negatively correlated with age. The relative CTRL-MPP did 
not significantly correlate with age. By far the most significant correlation was in the CTRL-
MLP population where we found that both the absolute and relative CTRL-MLP frequencies 
positively correlated with age. Both the absolute and relative numbers of the CTRL-pro B 
cells were significantly lower in the elderly control samples.  
The findings in the healthy control cohort were then contrasted with the age versus 
HSPC proportions in the patient cohort. Perhaps unsurprisingly most of the trends seen in 
controls were not emulated in patients HSPCs. The only HSPC population which ran 
counter to this was the pro B populations where the HSPC trends in controls were 
maintained i.e. lower pro B proportions as the patients got older. This negative correlation of 
pro B with age was statistically significant and was present in both the absolute and relative 
pro B. The most dramatic change was in the MLP, where the previously positive correlation 
of CTRL-MLP with age was completely lost in PT-MLP. The precise molecular 
mechanisms which could drive the observed loss of difference are yet to be elucidated. 
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When combined with the fact that when the patient groups were divided into older and 
younger patients (Figure 12), where it is visible that the most deregulation of the HSPC 
populations occurs in older patients, these data strongly suggest, that the presence of 
malignant cells has a much stronger impact on the elderly hematopoiesis, compared to the 
young. As a consequence, the disease related changes in HSPC frequencies are much more 
profound and hence override the age related changes normally observed in normal 
individuals as they get older. This disease driven effect on HSPCs on the other hand is less 
visible in younger patients. 
We then compared the whole patient cohort to age matched controls to get to the 
central question of whether patients with mature B-cell malignancies exhibit changes in 
their stem and progenitor populations. What we found was that irrespective of bone marrow 
infiltration or non-infiltration status, the relative proportions of HSCs (whole cohort, 
infiltrated cohort and non-infiltrated cohort) in patients were significantly increased in 
comparison to healthy controls, this was in contrast to the absolute proportions which were 
not significantly different from controls. This finding suggests that in both infiltrated and 
non-infiltrated cases of mature B-cell neoplasm the presence of malignancy is enough to 
induce increased HSC differentiation from the CD34+CD38- parent population. On the other 
hand all the MLPs (i.e. whole cohort, infiltrated cohort and non-infiltrated cohort) were 
significantly reduced in patient samples, suggesting that in diseased samples hematopoiesis 
favored the production of HSC and a concomitant reduction in MLP, or alternatively that 
HSC increases which do not translate to the more downstream MLP indicates a block in the 
production of downstream progenitors, this effect to a certain extent is visible in the 
reduction also of pro B proportions though this is not statistically significant.  
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The reasons for these observed changes are yet to be elucidated. It will however 
seem that there are two possibilities, the first being that the direct presence of malignant 
cells causes HSPC deregulation and/or secondly, that a soluble molecular mediator, which is 
released or influenced by malignant cells, is present in the bone marrow and regardless of 
bone marrow infiltration is able to cause HSPC deregulation remotely. The molecular 
mediators which might be implicated include cytokines, growth factors, or other types of 
messengers like microRNAs. Various molecules have been identified in connection with 
normal hematopoiesis though none have been demonstrated in disease states [87-89]. It is of 
interest and not yet known which of these populations (HSC vs. MLP) may be affected first 
and what kind of feedback mechanisms are present. It is clear however that the presence of 
malignancy has an effect on these populations. These findings are in agreement with what 
has been previously described by other authors namely that the presence of malignancy 
affects the stem cells compartment microenvironment and various signaling cascades 
involved in early hematopoiesis leading to deregulation of stem cells, progenitors and 
precursor cells [13, 90-92]. Incubation with CLL or DLBCL serum revealed changes at the 
mRNA level in healthy donor HSCs. The most changed genes were the lymphoid 
transcription factor IKAROS, the HSC proliferation regulator GATA2 and the 
multifunctional transcription factor MYC. 
It must be noted, that the changes in the MLP were so profound, that they were still 
apparent even in the absolute proportions analysis, on the other hand the absolute 
proportions of HSCs were not different from controls, which suggests that the primarily 
affected population is the MLP and not HSC, though this has to be proven. Further 
strengthening this line of thought is the observation that when looking at the HSPCs in the 
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individual diagnoses, the MLPs are the most consistently reduced population in all the 
diagnoses and this reduction is in both the absolute and relative proportions.  
Having established that HSPC deregulation exists in both disease infiltrated and 
uninfiltrated bone marrows we looked to see if the extent of infiltration was important. The 
absolute numbers of MPP, MLP and pro B negatively correlated with age. This data 
plausibly indicates that the presence of malignant cells oppresses hematopoiesis. The 
relative HSC and MLP showed negative correlation with infiltration but the relative 
numbers of MPP showed positive correlation with age, this data suggests a more complex 
hematopoiesis deregulation than mere spatial deregulation of hematopoiesis by malignant 
cells being present in the bone marrow. When looking at the individual diagnoses the most 
significant suppression of the absolute HSPC was observed in CLL (MPP, MLP and pro B 
with high statistical significance though HSC was not significantly different) which 
generally has the highest extent of bone marrow infiltrations. 
Hematopoiesis is a complex process orchestrated by various transcription factors, 
some with broad activity and some with a narrower scope. We asked whether transcriptional 
deregulation of important molecules driving hematopoiesis would be associated with the 
already observed differences in the composition of HSPCs between patients and healthy 
controls. The most differently expressed genes in patient HSCs included the HSC 
homeostasis regulator RUNX1 [93], the early lymphoid transcription factor IKZF1 
(IKAROS) [94], the HSC proliferation regulator GATA2 [95], the myeloid or B-cell proto-
oncogene BCL11A which functions upstream of EBF1 and PAX1 [96], the oncogenic 
transcription factor and master regulator of stem and progenitor cell biology forkhead box 
protein 1 (FOXP1) [97], SPI1 (PU.1) which is required for the development of the common 
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lymphoid progenitor (CLP) and the common myeloid progenitor (CMP) [98] and finally the 
multifunctional transcription factor MYC.  
The apoptosis related genes MCL1 and BCL2L1 were also much more increased in patients 
compared to controls. Some genes like CCND1, NOTCH1 and ZAP70 which control cell 
proliferation, differentiation and apoptosis were only expressed in patients and were not 
detectable in controls using our assay. The gene expression data also showed significantly 
higher expression of most of the tested transcription factors in patients compared to controls. 
This finding suggests that HSCs from patients with mature B-cell malignancies are more 
transcriptionally active compared to HSCs obtained from age matched healthy controls. 
Kikushige et al., 2011 described up regulation of IKZF1 in CLL derived HSCs [10]. 
Whether the up regulation of transcriptional activity might correlate with the increased 
relative numbers of HSC remains to be elucidated. The increased transcriptional activity and 
the increased expression of transcription factors, including early lymphoid differentiation 
associated transcription factors (e.g. IKZF1, SPI1 and BCL11A) does not correlate with the 
observed suppression of the earliest lymphoid progenitors. This might be explained by the 
bystander effect of the ongoing malignancy process if we assume the production and release 
in the circulation of external humoral factors that might modify the function and 
differentiation of HSCs through the initiation of various epigenetic changes or other 
pathways not covered by our gene expression analyses panel. 
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6 CONCLUSIONS 
In this study we were able to experimentally show that; 
1. The absolute and relative proportions of hematopoietic and progenitor stem cells of 
healthy subjects show changes which positively and negatively correlate with age. 
2. The observed age dependent changes in HSC, MPP and MLP population’s 
frequencies are lost in patients with mature B-cell neoplasms while the pro B cells 
maintain age correlation similar to healthy controls. 
3. HSPC frequency deregulation is more pronounced in older patients compared to 
younger patients. 
4. Patients with mature B-cell malignancies have altered HSPC frequencies when 
compared to healthy controls and these changes are both present in both Infiltrated 
and un-infiltrated disease states. 
5. The individual diagnoses of the mature B-cell malignancies demonstrate different 
deregulatory patterns of HSPC frequencies compared to CTRLs but all share a 
common similar deregulation of MLP populations. 
6. Absolute numbers of HSPC negatively correlate with BM infiltration, while their 
relative numbers show more complex pattern of correlation. 
7. The HSC compartment in mature B-cell malignancies displays deregulated 
transcription of key regulators of hematopoiesis and proto-oncogenes. 
8. There is evidence that the serum of patients with mature B-cell neoplasms contains a 
yet unidentified tumor released humoral factor/s, which can affect gene expression in 
healthy peripheral blood samples. 
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